EDIT - Editas Medicine Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
26%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -73.26%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -871.91%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 11.15
Debt Ratio is 0.18
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Editas Medicine Inc (EDIT) - www.editasmedicine.com
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.Exchange - NASDAQ
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Cynthia Collins
Employees - 235
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.